| 000 | 02648nam a22003497a 4500 | ||
|---|---|---|---|
| 008 | 220221s20212021 xxu||||| |||| 00| 0 eng d | ||
| 024 | _a10.1016/j.jceh.2021.12.003 [doi] | ||
| 024 | _aPMC8710401 [pmc] | ||
| 024 | _aS0973-6883(21)00583-1 [pii] | ||
| 040 | _aOvid MEDLINE(R) | ||
| 099 | _a34975241 | ||
| 245 | _aVaccination in Chronic Liver Disease: An Update. [Review] | ||
| 251 | _aJournal of Clinical & Experimental Hepatology. 2021 Dec 08 | ||
| 252 | _aJ. clin. exp. hepatol.. 2021 Dec 08 | ||
| 253 | _aJournal of clinical and experimental hepatology | ||
| 260 | _c2021 | ||
| 260 | _fFY2022 | ||
| 260 | _p2021 Dec 08 | ||
| 265 | _saheadofprint | ||
| 266 | _d2022-02-21 | ||
| 520 | _aPatients with chronic liver disease (CLD) with or without cirrhosis remain at risk of developing hepatic decompensation when infected with viral or bacterial pathogens. The Advisory Committee on Immunization Practices (ACIP) currently recommends vaccination in CLD against hepatitis A virus (HAV), hepatitis B virus (HBV), influenza, pneumococcus, herpes zoster, tetanus, diphtheria, pertussis, and SARS-CoV-2. Inactivated vaccines are preferred over live attenuated ones, especially in transplant recipients where live vaccines are contraindicated. As the severity of the liver disease progresses, vaccine efficacy declines, and therefore, vaccines should be ideally administered early in the disease course for optimal immune response. Despite the strong recommendations, overall vaccination coverage in CLD remains poor; however, it is encouraging to note that in recent years coverage against influenza and pneumococcus has shown some improvement. Inadequate access to healthcare, lack of information on vaccine safety, poor financial reimbursement for healthcare providers, and vaccine misinformation are often responsible for low immunization rates. This review summarizes the impact of vaccine-preventable illness in those with CLD, updated vaccine guidelines, seroconversion rates in the vaccinated, and barriers faced by healthcare professionals in immunizing those with liver disease. Copyright (c) 2021 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved. | ||
| 546 | _aEnglish | ||
| 650 | _aIN PROCESS -- NOT YET INDEXED | ||
| 651 | _aMedStar Union Memorial Hospital | ||
| 656 | _aInternal Medicine Residency | ||
| 657 | _aJournal Article | ||
| 657 | _aReview | ||
| 700 | _aNaqvi, Haider | ||
| 790 | _aAlukal JJ, Naqvi HA, Thuluvath PJ | ||
| 856 |
_uhttps://dx.doi.org/10.1016/j.jceh.2021.12.003 _zhttps://dx.doi.org/10.1016/j.jceh.2021.12.003 |
||
| 942 |
_cART _dArticle |
||
| 999 |
_c843 _d843 |
||